Online inquiry

IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15933MR)

This product GTTS-WQ15933MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets Felcat NGF gene. The antibody can be applied in Feline osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Felinized
RefSeq XM_004001117.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 100144611
UniProt ID A0A337SBN0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ15933MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8035MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ2461MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 181
GTTS-WQ15875MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XMT-1536
GTTS-WQ2603MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 557
GTTS-WQ15996MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ZW-25
GTTS-WQ15028MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ2957MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ANB-011
GTTS-WQ7769MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GS-5745
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW